587 related articles for article (PubMed ID: 19907437)
1. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.
Quach H; Ritchie D; Stewart AK; Neeson P; Harrison S; Smyth MJ; Prince HM
Leukemia; 2010 Jan; 24(1):22-32. PubMed ID: 19907437
[TBL] [Abstract][Full Text] [Related]
2. Properties of thalidomide and its analogues: implications for anticancer therapy.
Teo SK
AAPS J; 2005 Mar; 7(1):E14-9. PubMed ID: 16146335
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.
Hayashi T; Hideshima T; Akiyama M; Podar K; Yasui H; Raje N; Kumar S; Chauhan D; Treon SP; Richardson P; Anderson KC
Br J Haematol; 2005 Jan; 128(2):192-203. PubMed ID: 15638853
[TBL] [Abstract][Full Text] [Related]
4. Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs.
D'Souza C; Prince HM; Neeson PJ
Front Immunol; 2021; 12():632399. PubMed ID: 33746969
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide - current understanding of mechanistic properties.
Tageja N
Anticancer Agents Med Chem; 2011 Mar; 11(3):315-26. PubMed ID: 21426296
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.
Le Roy A; Prébet T; Castellano R; Goubard A; Riccardi F; Fauriat C; Granjeaud S; Benyamine A; Castanier C; Orlanducci F; Ben Amara A; Pont F; Fournié JJ; Collette Y; Mege JL; Vey N; Olive D
Front Immunol; 2018; 9():977. PubMed ID: 29780393
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Davies FE; Raje N; Hideshima T; Lentzsch S; Young G; Tai YT; Lin B; Podar K; Gupta D; Chauhan D; Treon SP; Richardson PG; Schlossman RL; Morgan GJ; Muller GW; Stirling DI; Anderson KC
Blood; 2001 Jul; 98(1):210-6. PubMed ID: 11418482
[TBL] [Abstract][Full Text] [Related]
8. [Immunomodulatory drugs (IMiDs)].
Oshima K; Ichinohe T
Nihon Rinsho; 2014 Jun; 72(6):1130-5. PubMed ID: 25016816
[TBL] [Abstract][Full Text] [Related]
9. IMiDs: a novel class of immunomodulators.
Knight R
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S24-30. PubMed ID: 16085014
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
Anderson KC
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory drugs in multiple myeloma.
Zangari M; Elice F; Tricot G
Expert Opin Investig Drugs; 2005 Nov; 14(11):1411-8. PubMed ID: 16255679
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma.
Görgün G; Calabrese E; Soydan E; Hideshima T; Perrone G; Bandi M; Cirstea D; Santo L; Hu Y; Tai YT; Nahar S; Mimura N; Fabre C; Raje N; Munshi N; Richardson P; Anderson KC
Blood; 2010 Oct; 116(17):3227-37. PubMed ID: 20651070
[TBL] [Abstract][Full Text] [Related]
13. The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma.
Fionda C; Abruzzese MP; Zingoni A; Cecere F; Vulpis E; Peruzzi G; Soriani A; Molfetta R; Paolini R; Ricciardi MR; Petrucci MT; Santoni A; Cippitelli M
Oncotarget; 2015 Sep; 6(27):23609-30. PubMed ID: 26269456
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.
Reddy N; Hernandez-Ilizaliturri FJ; Deeb G; Roth M; Vaughn M; Knight J; Wallace P; Czuczman MS
Br J Haematol; 2008 Jan; 140(1):36-45. PubMed ID: 17995965
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological properties of thalidomide and its analogues.
De Sanctis JB; Mijares M; Suárez A; Compagnone R; Garmendia J; Moreno D; Salazar-Bookaman M
Recent Pat Inflamm Allergy Drug Discov; 2010 Jun; 4(2):144-8. PubMed ID: 20307255
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulatory drugs as a therapy for multiple myeloma.
De Raeve H; Vanderkerken K
Curr Pharm Biotechnol; 2006 Dec; 7(6):415-21. PubMed ID: 17168657
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice.
Castelli R; Cannavò A; Conforti F; Grava G; Cortelezzi A
Immunopharmacol Immunotoxicol; 2012 Oct; 34(5):740-53. PubMed ID: 22401643
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide and lenalidomide in the treatment of multiple myeloma.
Kumar S; Rajkumar SV
Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
[TBL] [Abstract][Full Text] [Related]
19. Thalidomide analogs as emerging anti-cancer drugs.
Dredge K; Dalgleish AG; Marriott JB
Anticancer Drugs; 2003 Jun; 14(5):331-5. PubMed ID: 12782937
[TBL] [Abstract][Full Text] [Related]
20. Novel immunomodulatory compounds in multiple myeloma.
Saini N; Mahindra A
Expert Opin Investig Drugs; 2013 Feb; 22(2):207-15. PubMed ID: 23265189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
